SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

dapirolizumab pegol

BIIB·Biogen Inc.
BULLISH
Drug Impact Rating7/10
Trial phase
Phase 3
Time to market
If the PHOENYCS FLY study reads out positively in December 2026, regulatory submissions (BLA in the US, MAA in Europe) could follow in 2027, with potential approval in 2028-2029, assuming no additional trials are required.
Why 7/10
The next hard, dated catalyst is the Phase 3 PHOENYCS FLY topline readout, which Biogen management guided for the first half of December 2026 on its Q3 2026 earnings call. This is a pivotal readout for a second confirmatory study in SLE, roughly one month away, at a company where dapirolizumab is a meaningful but not sole pipeline asset (Biogen has MS, Alzheimer's, and other immunology programs).
Actionable Insight BULLISH

The next hard catalyst is the Phase 3 PHOENYCS FLY topline readout, which Biogen guided for the first half of December 2026 on its Q3 earnings call. A positive result would strengthen the case for regulatory filings in SLE; a miss would raise doubts about the drug's profile despite PHOENYCS GO's success. Watch for the readout timing and any pre-announcement.

Price Chart

Loading chart...

Executive Summary

Dapirolizumab pegol (DZP) is an investigational Fc-free anti-CD40L biologic for moderate-to-severe systemic lupus erythematosus (SLE), co-developed by UCB and Biogen (NASDAQ: BIIB). The first Phase 3 study (PHOENYCS GO) met its primary endpoint in September 2024, with 50% of patients achieving a BICLA response at week 48 versus 35% on placebo (p<0.001), and results were published in The Lancet in May 2026. A second confirmatory Phase 3 study (PHOENYCS FLY) was initiated in 2024, and Biogen's Q3 2026 earnings call guided for Phase 3 SLE results in the first half of December 2026. Today (Nov 9, 2026), UCB and Biogen presented additional post-hoc data at ACR Convergence 2026. The drug is not yet approved by any regulatory authority. Biogen is a large-cap biotech ($21.44B market cap) with a diversified portfolio, so dapirolizumab is a meaningful but not sole value driver.

How It Works

Dapirolizumab pegol is an injectable biologic drug that blocks a specific immune signaling pathway called CD40L (CD40 ligand). In lupus, the immune system mistakenly attacks the body's own tissues. CD40L acts like a key that turns on certain immune cells (B cells and T cells) that produce autoantibodies and inflammation. By blocking this key, dapirolizumab pegol aims to reduce the abnormal immune activity that drives lupus symptoms, without killing the immune cells themselves (it is Fc-free, meaning it does not trigger cell-killing immune responses).

Trial Status

The first Phase 3 study (PHOENYCS GO) completed and met its primary endpoint, with results published in The Lancet. A second Phase 3 study (PHOENYCS FLY, NCT06617325) was initiated in 2024, and Biogen guided for results in the first half of December 2026. Additional post-hoc and subgroup analyses continue to be presented at medical conferences (ACR 2026, EULAR 2026).

The Two-Sided Case

▲ Bull Case5
The Phase 3 PHOENYCS GO study met its primary endpoint with statistical significance: 50% of patients achieved BICLA response at week 48 vs 35% on placebo (p<0.001), and results were published in The Lancet.
Additional data presented at ACR 2026 (Nov 9, 2026) and EULAR 2026 showed benefits across multiple endpoints including fatigue reduction, flare rate reduction, and steroid-sparing effects.
The drug targets CD40L via a novel Fc-free mechanism, which may offer a differentiated profile versus existing SLE biologics that target BLyS (Benlysta) or type 1 interferon receptor (Saphnelo).
Biogen's Q3 2026 earnings call guided for Phase 3 SLE results in the first half of December 2026, suggesting the second pivotal study (PHOENYCS FLY) readout is imminent.
Analyst sentiment is bullish: 32 of 44 analysts rate BIIB Buy or Strong Buy, with a mean price target of $266 (7.3% upside from $248), and multiple firms raised targets in late October 2026.
▼ Bear Case4
SLE is a notoriously difficult indication with a history of Phase 3 failures; a second confirmatory trial (PHOENYCS FLY) is still needed and could fail to replicate PHOENYCS GO's positive result.
The SLE market already has two approved biologics (GSK's Benlysta and AstraZeneca's Saphnelo, the latter recently approved for subcutaneous self-administration), meaning dapirolizumab pegol would face established competition if approved.
Biogen is a large-cap company with a diversified portfolio; dapirolizumab pegol is only one of several pipeline assets, so even a positive readout may have limited impact on BIIB shares.
The drug is still investigational and not yet approved by any regulatory authority worldwide; regulatory timelines and requirements remain uncertain.

Upcoming Catalysts

  • Phase 3 PHOENYCS FLY topline readout expected in the first half of December 2026 (per Biogen Q3 2026 earnings call guidance)
  • Potential regulatory submissions (BLA/MAA) if PHOENYCS FLY is positive, likely in 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Biogen Inc. Press Release BIIB ·Originating report

Sources · 8

Hover a chip for the title
1 markets.businessinsider.com2 marketscreener.com3 seekingalpha.com4 nasdaq.com5 stockhouse.com6 wric.com7 lupus.org8 markets.financialcontent.com